Overview
- Investors sold off Zealand stock on Monday after the company and subsequent reports released granular Phase III data showing high patient withdrawal rates tied to gastrointestinal side effects.
- Zealand reported a 19% dropout rate attributed to GI events versus 2.9% on placebo, while other accounts put discontinuations at about 23–25% on active doses versus 5.4% for placebo.
- The trials nonetheless met efficacy endpoints, with weight loss up to about 16.6% versus roughly 3.2% for placebo and MRI sub‑study results showing large visceral and liver‑fat reductions.
- Analysts warned the tolerability profile could curb real‑world adoption against established GLP‑1 rivals, and brokers revised commercial risk assumptions as Zealand remains partnered with Boehringer Ingelheim for commercialization.
- Observers also flagged trial‑design issues that complicate interpretation, including reported use of prohibited GLP‑1 drugs in the placebo arm and a rigid protocol that may have raised discontinuations, leaving next steps and regulatory strategy in Boehringer’s hands.